Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48201, USA.
Brain Mind Institute, École Polytechnique Fédérale de Lausanne, School of Life Sciences, CH-1015 Lausanne, Switzerland.
Int J Mol Sci. 2021 Dec 29;23(1):363. doi: 10.3390/ijms23010363.
Methamphetamine (METH) is a highly abused psychostimulant that is neurotoxic to dopaminergic (DAergic) nerve terminals in the striatum and increases the risk of developing Parkinson's disease (PD). In vivo, METH-mediated DA release, followed by DA-mediated oxidative stress and mitochondrial dysfunction in pre- and postsynaptic neurons, mediates METH neurotoxicity. METH-triggered oxidative stress damages parkin, a neuroprotective protein involved in PD etiology via its involvement in the maintenance of mitochondria. It is not known whether METH itself contributes to mitochondrial dysfunction and whether parkin regulates complex I, an enzymatic complex downregulated in PD. To determine this, we separately assessed the effects of METH or DA alone on electron transport chain (ETC) complexes and the protein parkin in isolated striatal mitochondria. We show that METH decreases the levels of selected complex I, II, and III subunits (NDUFS3, SDHA, and UQCRC2, respectively), whereas DA decreases the levels only of the NDUFS3 subunit in our preparations. We also show that the selected subunits are not decreased in synaptosomal mitochondria under similar experimental conditions. Finally, we found that parkin overexpression does not influence the levels of the NDUFS3 subunit in rat striatum. The presented results indicate that METH itself is a factor promoting dysfunction of striatal mitochondria; therefore, it is a potential drug target against METH neurotoxicity. The observed decreases in ETC complex subunits suggest that DA and METH decrease activities of the ETC complexes via oxidative damage to their subunits and that synaptosomal mitochondria may be somewhat "resistant" to DA- and METH-induced disruption in mitochondrial ETC complexes than perikaryal mitochondria. The results also suggest that parkin does not regulate NDUFS3 turnover in rat striatum.
甲基苯丙胺(METH)是一种高度滥用的精神兴奋剂,它对纹状体中的多巴胺能(DAergic)神经末梢具有神经毒性,并增加了患帕金森病(PD)的风险。在体内,METH 介导的 DA 释放,随后是前突触和后突触神经元中的 DA 介导的氧化应激和线粒体功能障碍,介导了 METH 的神经毒性。METH 触发的氧化应激会损害 parkin,这是一种与 PD 病因学有关的神经保护蛋白,因为它参与了线粒体的维持。目前尚不清楚 METH 本身是否会导致线粒体功能障碍,以及 parkin 是否调节复合物 I,复合物 I 是 PD 中下调的一种酶复合物。为了确定这一点,我们分别评估了 METH 或 DA 单独对电子传递链(ETC)复合物和分离的纹状体线粒体中的 parkin 蛋白的影响。我们表明,METH 降低了选定的复合物 I、II 和 III 亚基(分别为 NDUFS3、SDHA 和 UQCRC2)的水平,而 DA 仅降低了我们制剂中 NDUFS3 亚基的水平。我们还表明,在类似的实验条件下,突触体线粒体中没有减少选定的亚基。最后,我们发现 parkin 的过表达不会影响大鼠纹状体中 NDUFS3 亚基的水平。所呈现的结果表明,METH 本身就是促进纹状体线粒体功能障碍的因素;因此,它是对抗 METH 神经毒性的潜在药物靶点。ETC 复合物亚基的减少表明,DA 和 METH 通过对其亚基的氧化损伤降低 ETC 复合物的活性,并且突触体线粒体可能对 DA 和 METH 诱导的线粒体 ETC 复合物破坏具有一定的“抵抗力”,而不是对核仁线粒体。结果还表明,parkin 不会调节大鼠纹状体中 NDUFS3 的周转。